Merck announced today that it will partner with 3 different large pharma companies to test its MK-3475 cancer immunotherapy with other durg combinations aimed at a variety of cancers. Merck will team with Pfizer on its drugs Inlyta and PF-2566 for multiple cancers. It pairs with Incyte and its drug INCB24360 against non-small cell lung cancer. And with Amgen and its anti-cancer virus talimogene laherparepvec. Merck will also look at 20 additional cancer applications through its own in-house R&D effort. This is a very hot target (PD-1) according to analysts and Merck is turning up its focus to try to win the race to the first therapies. BMS and Roche are te main competitors at this juncture with BMS seen as the leader in te field. See Fierce Biotech.
Posted by Bruce Lehr Feb 5th 2014